miRNAs as the important regulators of myasthenia gravis: involvement of major cytokines and immune cells

[1]  A. Punga,et al.  Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders , 2022, The Lancet Neurology.

[2]  Z. Yousefi,et al.  Dose-dependent effects of oleuropein administration on regulatory T-cells in patients with rheumatoid arthritis: An in vitro approach , 2022, International journal of immunopathology and pharmacology.

[3]  R. Mansouri,et al.  Evaluation of the expressed miR-129 and miR-549a in patients with multiple sclerosis , 2021, Advanced biomedical research.

[4]  B. Soliven,et al.  Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations , 2021, Journal of clinical medicine.

[5]  M. Leone,et al.  The epidemiology of myasthenia gravis , 2021, Journal of medicine and life.

[6]  P. Renjen.  Subgroup Classification of Myasthenia Gravis , 2020, Annals of Indian Academy of Neurology.

[7]  B. K. Vitturi,et al.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis , 2020, Neurological Sciences.

[8]  L. Kusner,et al.  Role of miRNAs in Normal and Myasthenia Gravis Thymus , 2020, Frontiers in Immunology.

[9]  Lijuan Zhang,et al.  Emerging Roles of Dysregulated MicroRNAs in Myasthenia Gravis , 2020, Frontiers in Neuroscience.

[10]  Y. Parman,et al.  CD4+ T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS , 2020, Frontiers in Immunology.

[11]  R. Mantegazza,et al.  miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids , 2020, Frontiers in Immunology.

[12]  A. Punga,et al.  Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine , 2020, Frontiers in Immunology.

[13]  S. Tzartos,et al.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics , 2020, Frontiers in Immunology.

[14]  Yajie Liu,et al.  Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10. , 2020, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[15]  Liqun Xu,et al.  MiR-181a regulates CD4+ T cell activation and differentiation by targeting IL-2 in the pathogenesis of myasthenia gravis. , 2019, European journal of immunology.

[16]  Shigeaki Suzuki,et al.  Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis , 2019, Scientific Reports.

[17]  M. Inghilleri,et al.  Italian recommendations for the diagnosis and treatment of myasthenia gravis , 2019, Neurological Sciences.

[18]  T. Ruck,et al.  Understanding the burden of refractory myasthenia gravis , 2019, Therapeutic advances in neurological disorders.

[19]  A. Punga,et al.  Circulating microRNA plasma profile in MuSK+ myasthenia gravis , 2018, Journal of Neuroimmunology.

[20]  K. Satyamoorthy,et al.  Clustered miRNAs and their role in biological functions and diseases , 2018, Biological reviews of the Cambridge Philosophical Society.

[21]  M. Freimer,et al.  Recent advances in understanding and managing myasthenia gravis , 2018, F1000Research.

[22]  D. Shanehbandi,et al.  Transcript Level of MicroRNA Processing Elements in Gastric Cancer , 2018, Journal of Gastrointestinal Cancer.

[23]  A. Punga,et al.  Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis , 2018, Journal of Neuroimmunology.

[24]  Q. Lu,et al.  Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets. , 2018, Cancer letters.

[25]  Jin-pin Li,et al.  miR-548k regulates CXCL13 expression in myasthenia gravis patients with thymic hyperplasia and in Jurkat cells , 2018, Journal of Neuroimmunology.

[26]  A. Punga,et al.  Circulating microRNAs as potential biomarkers in myasthenia gravis patients , 2018, Annals of the New York Academy of Sciences.

[27]  B. Eymard,et al.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review , 2017, Clinical Reviews in Allergy & Immunology.

[28]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[29]  I. Maclennan,et al.  Follicular Helper T Cells. , 2016, Annual review of immunology.

[30]  N. Gilhus,et al.  Myasthenia gravis — autoantibody characteristics and their implications for therapy , 2016, Nature Reviews Neurology.

[31]  Jin-pin Li,et al.  Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells. , 2016, Immunology letters.

[32]  A. Punga,et al.  Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis , 2016, Journal of Neuroimmunology.

[33]  B. Bruce,et al.  Relationship Between Age, Gender, and Race in Patients Presenting With Myasthenia Gravis With Only Ocular Manifestations , 2016, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[34]  Hao Zhou,et al.  MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10. , 2016, Clinical immunology.

[35]  A. Marx,et al.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society , 2016, Journal of Neurology.

[36]  Xiaojian Zhang,et al.  Disease-specific signature of serum miR-20b and its targets IL-8 and IL-25, in myasthenia gravis patients , 2016, European Cytokine Network.

[37]  Y. Huang,et al.  Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis , 2016, Clinical and Experimental Medicine.

[38]  A. Punga,et al.  Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients , 2015, Journal of the Neurological Sciences.

[39]  Nuha M. Alkhawajah,et al.  Treatment of Myasthenia Gravis in the Aged , 2015, Drugs & Aging.

[40]  K. Rajesh,et al.  Ocular Myasthenia Gravis: A Review. , 2015 .

[41]  Min Zhang,et al.  miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[42]  P. E. Van den Steen,et al.  CXCR3 ligands in disease and therapy. , 2015, Cytokine & growth factor reviews.

[43]  O. Parolini,et al.  Amniotic Membrane Mesenchymal Cells-Derived Factors Skew T Cell Polarization Toward Treg and Downregulate Th1 and Th17 Cells Subsets , 2014, Stem Cell Reviews and Reports.

[44]  O. Parolini,et al.  Amniotic Membrane Mesenchymal Cells-Derived Factors Skew T Cell Polarization Toward Treg and Downregulate Th1 and Th17 Cells Subsets , 2014, Stem Cell Reviews and Reports.

[45]  A. Nair,et al.  Ocular myasthenia gravis: A review , 2014, Indian journal of ophthalmology.

[46]  N. Gilhus,et al.  Antititin antibody in early‐ and late‐onset myasthenia gravis , 2014, Acta neurologica Scandinavica.

[47]  J. Maessen,et al.  Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. , 2014, Journal of autoimmunity.

[48]  L. Friberg,et al.  Cognitive impairment in early‐stage non‐demented Parkinson's disease patients , 2014, Acta neurologica Scandinavica.

[49]  J. Li,et al.  Delivery of an miR155 inhibitor by anti‐CD20 single‐chain antibody into B cells reduces the acetylcholine receptor‐specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis , 2014, Clinical and experimental immunology.

[50]  Bruno Eymard,et al.  Diagnostic and clinical classification of autoimmune myasthenia gravis. , 2014, Journal of autoimmunity.

[51]  A. Punga,et al.  Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker , 2013, Annals of clinical and translational neurology.

[52]  Xia Li,et al.  miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptor-related protein 6 , 2013, Cell Death and Disease.

[53]  D. Geng,et al.  Identification of Novel MicroRNA Signatures Linked to Experimental Autoimmune Myasthenia Gravis Pathogenesis: Down-Regulated miR-145 Promotes Pathogenetic Th17 Cell Response , 2013, Journal of Neuroimmune Pharmacology.

[54]  Jianwen Liu,et al.  MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1 , 2013, Journal of Clinical Immunology.

[55]  Fangyuan Zou,et al.  Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells. , 2012, International immunopharmacology.

[56]  D. Sanders,et al.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis? , 2012, Expert review of clinical immunology.

[57]  増田 眞之.  Clinical implication of peripheral CD4⁺CD25⁺ regulatory T cells and Th17 cells in myasthenia gravis patients , 2012 .

[58]  Nils Erik Gilhus,et al.  Myasthenia Gravis: A Review of Available Treatment Approaches , 2011, Autoimmune diseases.

[59]  L. Larrad,et al.  Increased serum interleukin‐17 levels in patients with myasthenia gravis , 2011, Muscle & nerve.

[60]  H. Utsumi,et al.  Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients , 2010, Journal of Neuroimmunology.

[61]  C. Shih,et al.  Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis , 2009, European journal of neurology.

[62]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[63]  S. Hubbard,et al.  Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSK , 2008, Cell.

[64]  L. McCorry.  Physiology of the autonomic nervous system. , 2007, American journal of pharmaceutical education.

[65]  B. Thanvi,et al.  Update on myasthenia gravis , 2004, Postgraduate Medical Journal.

[66]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[67]  N. Sarvetnick,et al.  Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis. , 2000, Immunology today.

[68]  R. Pirskanen,et al.  Tumor necrosis factor-α, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis , 1996, Journal of Neuroimmunology.

[69]  L. Phillips.  The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.

[70]  J. Garland.  The New England Journal of Medicine. , 1961, Canadian Medical Association journal.